Mortality risk in current and new antipsychotic Alzheimer's disease users: Large scale Japanese study

Alzheimer's and Dementia

Volumn 12, Issue 7, 2016, Pages 823-830

  Arai, Heii ^a   Nakamura, Yu ^b   Taguchi, Masamoto ^c   Kobayashi, Hiroyuki ^d,e   Yamauchi, Keita ^f   Schneider, Lon S ^g  

^a JUNTENDO UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c Ohgaki Municipal Hospital   (Japan)

^d TOHO UNIVERSITY   (Japan)

^e OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Antipsychotics; Dementia; Mortality risk; Prospective cohort study

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TIAPRIDE;

AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; FEMALE; FOLLOW UP; HUMAN; JAPANESE (PEOPLE); LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; MORTALITY RISK; MULTICENTER STUDY; ODDS RATIO; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; VERY ELDERLY; JAPAN; MORTALITY; RISK FACTOR; TRENDS;

AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; JAPAN; MALE; MORTALITY; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84969909324     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.03.006     Document Type: Article

References (26)

1. [1] Rabins, P.V., Blacker, B., Rovner, B.W., Rummans, T., Schneider, L.S., Tariot, P.N., et al., APA Work Group on Alzheimer's Disease and other Dementias. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. Am J Psychiatry 164 (2007), 5–56.
2. [2] Rodda, J., Morgan, S., Walker, Z., Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21 (2009), 813–824.
3. [3] Fox, C., Crugel, M., Maidment, I., Auestad, B.H., Coulton, S., Treloar, A., et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS One, 7, 2012, e35185.
4. [4] Seitz, D.P., Adunuri, N., Gill, S.S., Gruneir, A., Herrmann, N., Rochon, P., Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev, 2, 2011, CD008191.
5. [5] Howard, R.J., Juszczak, E., Ballard, C.G., Bentham, P., Brown, R.G., Bullock, R., et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357 (2007), 1382–1392.
6. [6] Paulose-Ram, R., Safran, M.A., Jonas, B.S., Gu, Q., Orwig, D., Trends in psychotropic medication use among U.S. adults. Pharmacoepidemiol Drug Saf 16 (2007), 560–570.
7. [7] Schneider, L.S., Tariot, P.N., Dagerman, K.S., Davis, S.M., Hsiao, J.K., Ismail, M.S., et al., CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 355 (2006), 1525–1538.
8. [8] Food and Drug Administration. FDA public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm053171.htm. Accessed August 12, 2015.
9. [9] Schneider, L.S., Dagerman, K.S., Insel, P., Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005), 1934–1943.
10. [10] Kales, H.C., Valenstein, M., Kim, H.M., McCarthy, J.F., Ganoczy, D., Cunningham, F., et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164 (2007), 1568–1576.
11. [11] Gill, S.S., Bronskill, S.E., Normand, S.L., Anderson, G.M., Sykoa, K., Lam, K., et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 146 (2007), 775–786.
12. [12] Wang, P.S., Schneeweiss, S., Avorn, J., Fischer, M.A., Mogun, H., Solomon, D.H., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 353 (2005), 2335–2341.
13. [13] Kales, H.C., Kim, H.M., Zivin, K., Valenstein, M., Seyfried, L.S., Chiang, C., et al. Risk of mortality among individual antipsychotics in patients with dementia. Am J Psychiatry 169 (2012), 71–79.
14. [14] Chan, T.C., Luk, J.K., Shea, Y.F., Lau, K.H., Chan, F.H., Yu, G.K., et al. Continuous use of antipsychotics and its association with mortality and hospitalization in institutionalized Chinese older adults: an 18-month prospective cohort study. Int Psychogeriatr 23 (2011), 1640–1648.
15. [15] Lopez, O.L., Becker, J.T., Chang, Y.F., Sweet, R.A., Aizenstein, H., Snitz, B., et al. The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry 170 (2013), 1051–1058.
16. [16] Raivio, M.M., Laurila, J.V., Strandberg, T.E., Tilvis, R.S., Pitkälä, K.H., Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 15 (2007), 416–424.
17. [17] Office of Inspector General, Department of Health and Human Services. Medicare atypical antipsychotic drug claims for elderly nursing home residents. 2011, Department of Health and Human Services, Washington D.C.
18. [18] Wang, P.S., Brookhart, M.A., Setoguchi, S., Patrick, A.R., Schneeweiss, S., Psychotropic medication use for behavioral symptoms of dementia. Curr Neurol Neurosci Rep 6 (2006), 490–495.
19. [19] American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV). 1995, American Psychiatric Association, Washington, DC, USA.
20. [20] Muraki, I., Yamagishi, K., Ito, Y., Fujieda, T., Ishikawa, Y., Miyagawa, Y., et al. Caregiver burden for impaired elderly Japanese with prevalent stroke and dementia under long-term care insurance system. Cerebrovasc Dis 25 (2008), 234–240.
21. [21] Sasaki, M., Arai, Y., Kumamoto, K., Abe, K., Arai, A., Mizuno, Y., Factors related to potentially harmful behaviors towards disabled older people by family caregivers in Japan. Int J Geriatr Psychiatry 22 (2007), 250–257.
22. [22] Yoshio, T., Inada, T., Uno, J., Miwa, T., Kitagawa, K., Miyahara, Y., et al. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Hum Psychopharmacol 27 (2012), 70–75.
23. [23] Rossom, R.C., Rector, T.S., Lederle, F.A., Dysken, M.W., Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?. J Am Geriatr Soc 58 (2010), 1027–1034.
24. [24] Langballe, E.M., Engdahl, B., Nordeng, H., Ballard, C., Aarsland, D., Selbæk, G., Short- and long-term mortality risk associated with the use of antipsychotics among 26,940 dementia outpatients: a population-based study. Am J Geriatr Psychiatry 22 (2014), 321–331.
25. [25] Ballard, C., Hanney, M.L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., et al., DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8 (2009), 151–157.
26. [26] Serrano-Pozo, A., Qian, J., Monsell, S.E., Frosch, M.P., Betensky, R.A., Hyman, B.T., Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol 72 (2013), 1182–1192.